Skip to main content

Table 2 Comparison of Tumor Clinicopathology and Radiolographic nodal status between patients with Pathological nodal status N1 and Pathological nodal status N0

From: Is sentinel lymph node biopsy without frozen section in early stage breast cancer sufficient in accordance with ACOSOG-Z0011? A retrospective review from King Chulalongkorn Memorial Hospital

  Total No. of Patient with Pathological node N1 No. of Patient with Pathological node N0 p-value
Location     0.189
 Right 108 9 (8.4%) 99 (91.6%)  
 Left 131 18 (13.8%) 113 (86.2%)  
Tumor size     0.095
 T1 (< 2 cm) 150 13 (11.9%) 133 (91.1%)  
 T2 (2–5 cm) 89 14 (14.8%) 75 (85.2%)  
Radiolographic node  < 0.001*
 Borderline 20 11 (55.0%) 9 (45.0%)  
 Negative 219 16 (7.4%) 203 (92.6%)  
Histologic grade     0.079
 1 48 1 (2.1%) 47 (97.9%)  
 2 132 18 (13.7%) 114 (86.3%)  
 3 59 8 (13.6%) 51 (86.4%)  
Histopathology     0.333
 IDC 195 27 (13.9%) 168 (86.1%)  
 ILC 9 0 (0%) 9 (100%)  
 DCISM 15 0 (0%) 15 (100%)  
 Mucinous 10 0 (0%) 10 (100%)  
 Papillary 6 0 (0%) 6 (100%)  
 Tubular 1 0 (0%) 1 (100%)  
 Mixed 3 0 (0%) 3 (100%)  
Lymphovascular invasion  < 0.001*
 Yes 39 18 (46.2%) 21 (53.8%)  
 No 200 9 (4.5%) 191 (95.5%)  
Estrogen receptor     0.961
 Positive 185 21 (11.4%) 164 (88.6%)  
 Negative 54 6 (11.1%) 48 (88.9%)  
Progesterone receptor 0.834
 Positive 155 18 (11.7%) 137 (88.3%)  
 Negative 84 9 (10.8%) 75 (89.2%)  
HER-2     0.967
 Positive 49 6 (12.2%) 43 (87.8%)  
 Negative 180 20 (11.1%) 160 (88.9%)  
 Not known 10 1 (10.0%) 9 (90.0%)  
 Total 239 27 212  
  1. IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; DCISM, ductal carcinoma in situ with microinvasion; HER-2, human epidermal growth factor receptor 2